Name (Synonyms) | Correlation | |
---|---|---|
drug1363 | Lopinavir and Ritonavir Tablets Wiki | 0.71 |
drug2753 | basic treatment Wiki | 0.50 |
drug2114 | Routine care for COVID-19 patients Wiki | 0.50 |
drug923 | Favipiravir Wiki | 0.17 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
There are 2 clinical trials
The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage of these drugs in the future .
Description: Novel coronaviral nucleic acid is measured in nose / throat swab at each time point.
Measure: The rate of virus inhibition Time: Day 0, 2, 4, 7, 10, 14 and 21Description: Body temperature will be followed everyday during time frame.
Measure: The disease prorogation-temperature Time: Day 0 till day 21Description: Respiratory rate will be followed everyday during time frame.
Measure: The disease prorogation-respiratory function 1 Time: Day 0 till day 21Description: Oxygen saturation of blood will be followed everyday during time frame.
Measure: The disease prorogation-respiratory function 2 Time: Day 0 till day 21Description: Chest imaging will be taken at each time point.
Measure: The disease prorogation-respiratory function 3 Time: Day 0, 4, 7, 10, 14 and 21Description: Blood pressure and heart rate will be followed everyday during time frame.
Measure: Patients health condition-routine test Time: Day 0 till day 21Description: Liver function will be assessed as AST, ALT and TBIL at each time point.
Measure: Patients health condition-liver function Time: Day 0, 4, 7, 10, 14 and 21Description: Kidney function will be assessed as eGFR and creatine clearance rate at each time point.
Measure: Patients health condition-kidney function Time: Day 0, 4, 7, 10, 14 and 21Description: Blood routine and myocardial enzyme will be measured at each time point.
Measure: Patients health condition-other blood routine test Time: Day 0, 4, 7, 10, 14 and 21Description: Flow cytometry classification and counting and cytokines will be measured at each time point.
Measure: Patients health condition-blood routine test Time: Day 0, 4, 7, 10, 14 and 21In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.
Description: virus negative conversion rate in second week, overall virus negative conversion rate
Measure: Virus negative conversion rate Time: 14-20 daysDescription: defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48h
Measure: Antipyretic rate Time: 14-20 daysDescription: time to relieve symptoms of fever, cough, dyspnea, myalgia, etc
Measure: Symptom relief time Time: 14-20 daysDescription: no adjuvant oxygen therapy, resting oxygen saturation>95%, oxygenation index>350
Measure: Finger oxygen improvement rate Time: 14-20 daysDescription: Mild, common type progression to severe or critical illness rate
Measure: Disease progression rate Time: 14-20 days